HJB647 在射血分数降低的心力衰竭参与者中的安全性和耐受性研究
一项多中心、随机、受试者与研究者双盲、安慰剂对照交叉研究,旨在探究HJB647在射血分数降低的慢性稳定性心力衰竭患者中的安全性、耐受性和药代动力学
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
研究概览
详细说明
This is a multi-center, randomized, participant- and investigator- blinded, placebo- controlled crossover study to investigate the safety, tolerability, and pharmacokinetics of HJB647 in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
The study will consist of approximately 12 participants randomly assigned in a 1:1:1 ratio to one of three 3-day treatment sequences comprised of two doses of HJB647 and placebo. Dosing of the HJB647 and placebo is planned for 3 consecutive days. Participants will be domiciled during study drug administration period for close monitoring with a follow-up in-clinic visit on Day 7. A safety call will be performed on Day 33.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Novartis Pharmaceuticals
- 电话号码:1-888-669-6682
- 邮箱:novartis.email@novartis.com
研究联系人备份
- 姓名:Novartis Pharmaceuticals
- 电话号码:+41613241111
学习地点
-
-
Quebec
-
Montreal、Quebec、加拿大、H1T 1C8
- 招聘中
- Novartis Investigative Site
-
Sherbrooke、Quebec、加拿大、J1E 0N8
- 招聘中
- Novartis Investigative Site
-
-
-
-
Florida
-
Bradenton、Florida、美国、34208
- 招聘中
- Synergy Healthcare
-
首席研究员:
- Patrick Weston
-
接触:
- Shannon Stickels
- 邮箱:sstickels@synergyhealthcorp.com
-
Inverness、Florida、美国、34452
- 招聘中
- Nature Coast Clinical Research LLC
-
首席研究员:
- Rafik Abadier
-
接触:
- Jill Barnett
- 电话号码:+1 352 341 2100
- 邮箱:jbarnett@flourishresearch.com
-
Jacksonville、Florida、美国、32216
- 招聘中
- Jacksonville Center for Clinical
-
首席研究员:
- Michael J Koren
-
接触:
- Sara Villotti
- 电话号码:+1 904 730 0101
- 邮箱:svillotti@flourishresearch.com
-
Miami Lakes、Florida、美国、33014
- 招聘中
- Inpatient Research Clinical LLC
-
首席研究员:
- Alexis Gutierrez
-
接触:
- Lazaro Rivero
- 电话号码:+1 786 502 4303
- 邮箱:lrivero@inpatientresearch.com
-
Winter Park、Florida、美国、32789
- 招聘中
- Flourish Research
-
首席研究员:
- Monica Aggarwal
-
接触:
- Sara Contreras
- 邮箱:scontreras@flourishresearch.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Participants eligible for inclusion in this study must meet all of the following criteria:
- Men and women aged 18 years or older
- Stable NYHA functional class II-III
- LVEF <50%
- NT-proBNP ≥600 pg/ml if in sinus rhythm or ≥900 pg/ml if in atrial fibrillation at screening
- On stable standard of care therapy with sacubitril/valsartan for at least 4 weeks before screening.
Exclusion Criteria:
Participants will be deemed ineligible for inclusion if they meet any of the following exclusion criteria:
- Acute decompensated heart failure within 3 months prior to screening
- SBP <105 mmHg at screening or baseline.
- Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, PCI, or carotid angioplasty within the 6 months prior to screening
- Hemodynamically significant mitral and/or aortic valve disease, or any prior valve replacement, except mitral regurgitation secondary to LV dilation at screening
- eGFR <30 ml/min/1.73m2 at screening, as measured by the CKD-EPI formula
- BMI >40 kg/m2
- Strong CYP3A4 inhibitors or inducers, sGC activators (vericiguat), PDE5 inhibitors, and nitroglycerin products
- Women of childbearing potential
Further eligibility criteria might apply in alignment with the trial protocol.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo
Taken by mouth as capsules |
Placebo control in capsule form |
|
实验性的:HJB647 low dose
Taken by mouth as capsule |
Study drug low dose in capsule form |
|
实验性的:HJB647 high dose
Taken by mouth as capsule |
Study drug high dose in capsule form |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with Adverse Events (AEs)
大体时间:Up to 33 days
|
Number of participants with AEs as a measure of safety and tolerability |
Up to 33 days
|
|
Number of participants with clinically significant changes in vital signs
大体时间:Up to 33 days
|
Number of participants with clinically significant changes in Systolic Blood Pressure, Diastolic Blood Pressure, Heart Rate, Electrocardiogram and hyposensitive events as a measure of adverse events |
Up to 33 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pharmacokinetics: Maximum concentration (Cmax)
大体时间:Up to 7 days
|
Maximum concentration (Cmax) of the trial drug in participants' blood |
Up to 7 days
|
|
Pharmacokinetics: Time to reach maximum plasma concentration (Tmax)
大体时间:Up to 7 days
|
Time to require the trial drug to reach its maximum concentration in participants blood |
Up to 7 days
|
|
Pharmacokinetics: Area Under the Concentration-Time Curve from dosing form to the last measurable concentration (AUClast)
大体时间:Up to 7 days
|
Area under the curve from time zero to the last measurable concentration sampling time |
Up to 7 days
|
合作者和调查者
调查人员
- 研究主任:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.